Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Florian von Raison"'
Autor:
Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral e
Externí odkaz:
https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46
Autor:
Florian von Raison, Caroline Sincock, Robert J. Fox, Charlotte E. Teunissen, Douglas L. Arnold, Tatiana Plavina, David Leppert, Raju Kapoor, Kathryn E Smith, Jens Kuhle, Elizabeth Walker, Finn Sellebjerg, Roberto Furlan, Christopher Harp, Ilir Topalli, Mark Allegretta, Manuel Comabella, William Carroll
Publikováno v:
Kapoor, R, Smith, K E, Allegretta, M, Arnold, D L, Carroll, W, Comabella, M, Furlan, R, Harp, C, Kuhle, J, Leppert, D, Plavina, T, Sellebjerg, F, Sincock, C, Teunissen, C E, Topalli, I, von Raison, F, Walker, E & Fox, R J 2020, ' Serum neurofilament light as a biomarker in progressive multiple sclerosis ', Neurology, vol. 95, no. 10, pp. 436-444 . https://doi.org/10.1212/WNL.0000000000010346
Neurology, 95(10), 436-444. Lippincott Williams and Wilkins
Neurology
article-version (Version of Record) 3
Neurology, 95(10), 436-444. Lippincott Williams and Wilkins
Neurology
article-version (Version of Record) 3
There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc29e43e8b7004935d7a7345427d01f6
https://doi.org/10.1212/wnl.0000000000010346
https://doi.org/10.1212/wnl.0000000000010346
Autor:
Emmanuel Zuber, Francesca Callegari, Peter Quarg, Mouna Akacha, Shaloo Pandhi, Florian Von Raison
Publikováno v:
Statistics in Biopharmaceutical Research. 12:39-44
An estimand clearly defines the target treatment effect to be estimated in a clinical trial. A recently published draft International Conference on Harmonization E9 addendum introduces the concept ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56f18ef8cf48f9add409bfd7b83b9d70
https://doi.org/10.1080/19466315.2019.1629997
https://doi.org/10.1080/19466315.2019.1629997
Autor:
Gerd K. Rosenkranz, George Apostol, Alessandra Murgia, Christian Wolf, Vincent des Portes, Randi J Hagerman, Elizabeth Berry-Kravis, Barbara Koumaras, Andrew C. Stanfield, Sébastien Jacquemont, Florian Von Raison
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Scientific Reports
Scientific reports, vol 8, iss 1
Hagerman, R, Jacquemont, S, Berry-Kravis, E, Des Portes, V, Stanfield, A, Koumaras, B, Rosenkranz, G, Murgia, A, Wolf, C, Apostol, G & von Raison, F 2018, ' Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents ', Scientific Reports, vol. 8, no. 1, pp. 16970 . https://doi.org/10.1038/s41598-018-34978-4
Scientific reports, vol. 8, no. 1, pp. 16970
Scientific Reports
Scientific reports, vol 8, iss 1
Hagerman, R, Jacquemont, S, Berry-Kravis, E, Des Portes, V, Stanfield, A, Koumaras, B, Rosenkranz, G, Murgia, A, Wolf, C, Apostol, G & von Raison, F 2018, ' Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents ', Scientific Reports, vol. 8, no. 1, pp. 16970 . https://doi.org/10.1038/s41598-018-34978-4
Scientific reports, vol. 8, no. 1, pp. 16970
Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64f802041339772bf5d7fcef235cf245
https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46
https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46
Autor:
Florian Von Raison, Randall L. Carpenter, Will Spooren, George Apostol, Jacqueline N. Crawley, Eva Loth, Elizabeth Berry-Kravis, Lothar Lindemann, Vincent des Portes, Farah Hossain, Mark F. Bear, Randi J Hagerman, Sebastian H. Scharf, Baltazar Gomez-Mancilla, Paul P. Wang, David R Hessl, Sébastien Jacquemont, Fabrizio Gasparini, Aia E. Jønch, Aurore Curie
Publikováno v:
Other repository
Berry-Kravis, E M, Lindemann, L, Jønch, A E, Apostol, G, Bear, M F, Carpenter, R L, Crawley, J N, Curie, A, Des Portes, V, Hossain, F, Gasparini, F, Gomez-Mancilla, B, Hessl, D, Loth, E, Scharf, S H, Wang, P P, Von Raison, F, Hagerman, R, Spooren, W & Jacquemont, S 2018, ' Drug development for neurodevelopmental disorders : lessons learned from fragile X syndrome ', Nature Reviews. Drug Discovery, vol. 17, no. 4, pp. 280–299 . https://doi.org/10.1038/nrd.2017.221
Nature reviews. Drug discovery, vol 17, iss 4
Berry-Kravis, E M, Lindemann, L, Jønch, A E, Apostol, G, Bear, M F, Carpenter, R L, Crawley, J N, Curie, A, Des Portes, V, Hossain, F, Gasparini, F, Gomez-Mancilla, B, Hessl, D, Loth, E, Scharf, S H, Wang, P P, Von Raison, F, Hagerman, R, Spooren, W & Jacquemont, S 2018, ' Drug development for neurodevelopmental disorders : lessons learned from fragile X syndrome ', Nature Reviews. Drug Discovery, vol. 17, no. 4, pp. 280–299 . https://doi.org/10.1038/nrd.2017.221
Nature reviews. Drug discovery, vol 17, iss 4
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07282a248315c1903424992a9b10d48b
https://doi.org/10.1038/nrd.2017.221
https://doi.org/10.1038/nrd.2017.221
Autor:
Florian Von Raison, Nalina Dronamraju, Fabrizio Stocchi, Amy Shah, Ana Graf, Claudia Trenkwalder, Chris Kenney, Werner Poewe
Publikováno v:
Movement Disorders. 31:1054-1058
Background Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study 1) and modified-release (study 2) mavoglurant formulations in PD l-dopa-induced dyskinesia. Methods Patients were random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55cebc203aa02fe5492ef29c898598dc
https://doi.org/10.1002/mds.26585
https://doi.org/10.1002/mds.26585
Autor:
Fabrizio Gasparini, Elizabeth Berry-Kravis, George Apostol, Sébastien Jacquemont, Florian Von Raison, Randi J Hagerman, Baltazar Gomez-Mancilla, Vincent des Portes, Mike Ufer
Publikováno v:
Psychopharmacology
Psychopharmacology, 2014, 231, pp.Issue : 6 Pages : 1237-1250. ⟨10.1007/s00213-013-3289-0⟩
Psychopharmacology, vol 231, iss 6
Psychopharmacology, 2014, 231, pp.Issue : 6 Pages : 1237-1250. ⟨10.1007/s00213-013-3289-0⟩
Psychopharmacology, vol 231, iss 6
Rationale Advances in understanding the underlying mechanisms of conditions such as fragile X syndrome (FXS) and autism spectrum disorders have revealed heterogeneous populations. Recent trials of novel FXS therapies have highlighted several challeng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0774641b2a1764c8bff6dffa6dc91688
https://doi.org/10.1007/s00213-013-3289-0
https://doi.org/10.1007/s00213-013-3289-0
Autor:
Randi J Hagerman, Marc Brinkman, Barbara Koumaras, Thomas Jaecklin, Sébastien Jacquemont, Gottfried Maria Barth, George Apostol, Elizabeth Berry-Kravis, Florian Von Raison, Karin Rerat, Perrine Charles, Liansheng Zhu, Jeannie Visootsak, Vincent des Portes
Publikováno v:
Science Translational Medicine. 8
Fragile X syndrome (FXS), the most common cause of inherited intellectual disability and autistic spectrum disorder, is typically caused by transcriptional silencing of the X-linked FMR1 gene. Work in animal models has described altered synaptic plas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c3a36314bbc1e7ae8fab1a174c2c806
https://doi.org/10.1126/scitranslmed.aab4109
https://doi.org/10.1126/scitranslmed.aab4109
Autor:
Florian von Raison
Publikováno v:
Developing Drug Products in an Aging Society ISBN: 9783319430973
In Europe, the population is ageing rapidly. Older people are taking many medicinal products daily, and these may not necessarily be suitable for them. According to research studies, older patients are underrepresented in clinical trials, especially
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6023695efa9fc0410175992f1e517c82
https://doi.org/10.1007/978-3-319-43099-7_8
https://doi.org/10.1007/978-3-319-43099-7_8
Autor:
Claudia, Trenkwalder, Fabrizio, Stocchi, Werner, Poewe, Nalina, Dronamraju, Chris, Kenney, Amy, Shah, Florian, von Raison, Ana, Graf
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 31(7)
Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study 1) and modified-release (study 2) mavoglurant formulations in PD l-dopa-induced dyskinesia.Patients were randomized to mavoglurant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87287648f95de2163f90197ce471b481
https://pubmed.ncbi.nlm.nih.gov/27214258
https://pubmed.ncbi.nlm.nih.gov/27214258